Researchers are also studying whether they may lower the risk of certain serious illnesses, including some cancers. “GLP-1s ...

ImmunityBio (IBRX) stock falls as the FDA issues a warning letter regarding a TV commercial and a podcast related to the ...

Dieticians are warning that GLP-1 use can lead to extreme malnutrition, manifesting in diseases like scurvy, amid findings that the vast majority of studies fail to consider patients’ eating habits.

A popular class of drugs for treating diabetes and obesity may reduce addiction, including abuse of alcohol, tobacco, cannabis, opioids and cocaine, according to research published March 4 by ...

North Carolina Poison Control is warning GLP-1 drug users to use caution when taking the medication. Poison control said last year it averaged one to two calls a day about GLP-1 drugs with 80 percent ...

GLP-1 drugs — including Ozempic and Wegovy — may be tied to a slightly higher risk of osteoporosis and gout, according to research presented Monday at the American Academy of Orthopaedic Surgeons’ ...

Many patients are getting GLP-1s from websites and medical spas. But there’s much less oversight. By Simar Bajaj Since the GLP-1 boom began, obesity drugs haven’t just been prescribed in clinics; ...

GLP-1 medications are more popular than ever, as science continues to discover new ways they can be used to address a variety of health conditions—from managing type 2 diabetes and obesity to reducing ...

GLP-1 medications mimic a natural hormone that controls appetite, blood sugar, and digestion. Monthly costs range from $199 to over $1,300, depending on the specific medication and insurance coverage.

Dushay is an assistant professor of medicine at Harvard Medical School and an attending endocrinologist at Beth Israel Deaconess Medical Center. It makes my head spin to think about how much GLP-1s ...

“Micronutrient deficiencies during GLP-1 therapy are a common consequence rather than a rare adverse effect. Additionally, findings illustrate that GLP-1 RA [receptor agonist]-associated nutritional ...

GLP-1 therapies continue to reshape chronic disease treatment, triggering regulatory updates, new clinical findings and intensifying competition across the pharmaceutical market. On Jan. 13, the FDA ...